NextCure (NASDAQ:NXTC) will report on Q4 2021.
HC Wainwright & Co. Maintains Buy on Krystal Biotech, Lowers Price Target to $107
HC Wainwright & Co. analyst Joseph Pantginis maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $124 to $107.